Morgan Dempsey Capital Management’s AbbVie ABBV Stock Holding History

Morgan Dempsey Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.7K	Hold	100	–	–	0.01%	97
2025 Q4	$22.8K	Hold	100	–	–	0.01%	96
2025 Q3	$23.2K	Hold	100	–	–	0.01%	101
2025 Q2	$18.6K	Buy	+100	New	+$18.6K	0.01%	103
2016 Q3	–	Sell	-29	Closed	-$2K	–	155
2016 Q2	$2K	Buy	+29	New	+$1.77K	﹤0.01%	170

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Dempsey Capital Management's ABBV Position: Q1 2026 in Review

Morgan Dempsey Capital Management held its AbbVie (ABBV) position steady in Q1 2026 at 100 shares worth $21.7K. The position accounts for 0.01% of the portfolio, ranked #97.

Morgan Dempsey Capital Management first reported a position in ABBV in Q2 2016 and has held it in 5 quarters since. The position peaked at $23.2K in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Morgan Dempsey Capital Management held 100 shares of AbbVie worth $21.7K as of Q1 2026.
Morgan Dempsey Capital Management left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.01% of Morgan Dempsey Capital Management's portfolio in Q1 2026, its #97 holding.
Morgan Dempsey Capital Management first reported a position in AbbVie in Q2 2016 and has held it in 5 quarters since.
Morgan Dempsey Capital Management's AbbVie position peaked at $23.2K in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Morgan Dempsey Capital Management's 13F filing for Q1 2026, filed 6 May 2026.